CCL2 promotes EGFR-TKIs resistance in non-small cell lung cancer via the AKT-EMT pathway
Acta Biochimica et Biophysica Sinica · 01.10.2024 · 56 (10) · 1549-1560
DOI: 10.3724/abbs.2024106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, online erschienen am 03.07.2024. Verfasst von Yunlian Diao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Prevention and Treatment of Infectious Diseases, Jiangxi Medical Center for Major Public Health Events, the Firs…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Chemokine CCL2, Drug Resistance, Neoplasm, ErbB Receptors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) represents a primary cause of treatment failure in non-small cell lung cancer (NSCLC) patients. Chemokine (C-C motif) ligand 2 (CCL2) is recently found to play a pivotal role in determining anti-cancer treatment response. However, the role and mechanism of CCL2 in the development of EGFR-TKIs resistance have not been fully elucidated. In the present study, we focus on the function of CCL2 in the development of acquired resistance to EGFR-TKIs in NSCLC cells. Our results show that CCL2 is aberrantly upregulated in EGFR-TKIs-resistant NSCLC cells and that CCL2 overexpression significantly diminishes sensitivity to EGFR-TKIs. Conversely, CCL2 suppression by CCL2 synthesis inhibitor, bindarit, or CCL2 knockdown can reverse this resistance. CCL2 upregulation can also lead to enhanced migration and increased expressions of epithelial-mesenchymal transition (EMT) markers in EGFR-TKI-resistant NSCLC cells, which could also be rescued by CCL2 knockdown or inhibition. Furthermore, our findings suggest that CCL2-dependent EGFR-TKIs resistance involves the AKT-EMT signaling pathway; inhibition of this pathway effectively attenuates CCL2-induced cell migration and EMT marker expression. In summary, CCL2 promotes the development of acquired EGFR-TKIs resistance and EMT while activating AKT signaling in NSCLC. These insights suggest a promising avenue for the development of CCL2-targeted therapies that prevent EGFR-TKIs resistance in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Prevention and Treatment of Infectious Diseases, Jiangxi Medical Center for Major Public Health Events, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, N…
- Jiangxi Provincial Key Laboratory of Respiratory Diseases, Jiangxi Institute of Respiratory Disease, Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital, Jiangxi Medical College, Nanchang…
- The Clinical Trial Research Center, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
- Department of Physiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Zitieren
APA
Diao, Y., Huang, S., Liu, F., Liao, S., Guan, C., Xiong, X., Zhang, P., Li, J., Zhang, W., & Ying, Y. (2024). CCL2 promotes EGFR-TKIs resistance in non-small cell lung cancer via the AKT-EMT pathway. Acta Biochimica et Biophysica Sinica, 56(10), 1549-1560. https://doi.org/10.3724/abbs.2024106
Vancouver
Diao Y, Huang S, Liu F, Liao S, Guan C, Xiong X, et al. CCL2 promotes EGFR-TKIs resistance in non-small cell lung cancer via the AKT-EMT pathway. Acta Biochimica et Biophysica Sinica. 2024;56(10):1549-1560. doi:10.3724/abbs.2024106
BibTeX
@article{Diao2024,
author = {Diao, Yunlian and Huang, Shibo and Liu, Fangpeng and Liao, Shu and Guan, Chenxi and Xiong, Xiaojian and Zhang, Ping and Li, Junyao and Zhang, Wei and Ying, Ying},
title = {CCL2 promotes EGFR-TKIs resistance in non-small cell lung cancer via the AKT-EMT pathway},
journal = {Acta Biochimica et Biophysica Sinica},
year = {2024},
volume = {56},
number = {10},
pages = {1549--1560},
doi = {10.3724/abbs.2024106}
}
EUVIMED